Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: A Multi-Institutional Retrospective Review of 87 Patients

Kazuhiko Ogawa, Katsumasa Nakamura, Kazuo Hatano, Takashi Uno, Nobukazu Fuwa, Jun Itami, Shizuo Kojya, Torahiko Nakashima, Akihiko Shinhama, Takashi Nakagawa, Takafumi Toita, Mitsuhiro Sakai, Takeshi Kodaira, Mikio Suzuki, Hisao Ito, Sadayuki Murayama

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.

Original languageEnglish
Pages (from-to)1326-1334
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume68
Issue number5
DOIs
Publication statusPublished - Aug 1 2007

Fingerprint

middle ear
Ear Canal
canals
prognosis
ear
Middle Ear
Squamous Cell Carcinoma
cancer
Disease-Free Survival
radiation therapy
chemotherapy
Radiotherapy
surgery
Drug Therapy
margins
Survival Rate
Therapeutics
Karnofsky Performance Status
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear : A Multi-Institutional Retrospective Review of 87 Patients. / Ogawa, Kazuhiko; Nakamura, Katsumasa; Hatano, Kazuo; Uno, Takashi; Fuwa, Nobukazu; Itami, Jun; Kojya, Shizuo; Nakashima, Torahiko; Shinhama, Akihiko; Nakagawa, Takashi; Toita, Takafumi; Sakai, Mitsuhiro; Kodaira, Takeshi; Suzuki, Mikio; Ito, Hisao; Murayama, Sadayuki.

In: International Journal of Radiation Oncology Biology Physics, Vol. 68, No. 5, 01.08.2007, p. 1326-1334.

Research output: Contribution to journalArticle

Ogawa, K, Nakamura, K, Hatano, K, Uno, T, Fuwa, N, Itami, J, Kojya, S, Nakashima, T, Shinhama, A, Nakagawa, T, Toita, T, Sakai, M, Kodaira, T, Suzuki, M, Ito, H & Murayama, S 2007, 'Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: A Multi-Institutional Retrospective Review of 87 Patients', International Journal of Radiation Oncology Biology Physics, vol. 68, no. 5, pp. 1326-1334. https://doi.org/10.1016/j.ijrobp.2007.01.052
Ogawa, Kazuhiko ; Nakamura, Katsumasa ; Hatano, Kazuo ; Uno, Takashi ; Fuwa, Nobukazu ; Itami, Jun ; Kojya, Shizuo ; Nakashima, Torahiko ; Shinhama, Akihiko ; Nakagawa, Takashi ; Toita, Takafumi ; Sakai, Mitsuhiro ; Kodaira, Takeshi ; Suzuki, Mikio ; Ito, Hisao ; Murayama, Sadayuki. / Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear : A Multi-Institutional Retrospective Review of 87 Patients. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 68, No. 5. pp. 1326-1334.
@article{59694c0493224a08ad2256033b66bfd5,
title = "Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: A Multi-Institutional Retrospective Review of 87 Patients",
abstract = "Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61{\%}) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39{\%}). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55{\%} and 54{\%}, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83{\%}, 45{\%}, and 0 in the RT group (p < 0.0001) and 75{\%}, 75{\%}, and 46{\%} in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83{\%}, 55{\%}, and 38{\%}, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.",
author = "Kazuhiko Ogawa and Katsumasa Nakamura and Kazuo Hatano and Takashi Uno and Nobukazu Fuwa and Jun Itami and Shizuo Kojya and Torahiko Nakashima and Akihiko Shinhama and Takashi Nakagawa and Takafumi Toita and Mitsuhiro Sakai and Takeshi Kodaira and Mikio Suzuki and Hisao Ito and Sadayuki Murayama",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.ijrobp.2007.01.052",
language = "English",
volume = "68",
pages = "1326--1334",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear

T2 - A Multi-Institutional Retrospective Review of 87 Patients

AU - Ogawa, Kazuhiko

AU - Nakamura, Katsumasa

AU - Hatano, Kazuo

AU - Uno, Takashi

AU - Fuwa, Nobukazu

AU - Itami, Jun

AU - Kojya, Shizuo

AU - Nakashima, Torahiko

AU - Shinhama, Akihiko

AU - Nakagawa, Takashi

AU - Toita, Takafumi

AU - Sakai, Mitsuhiro

AU - Kodaira, Takeshi

AU - Suzuki, Mikio

AU - Ito, Hisao

AU - Murayama, Sadayuki

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.

AB - Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.

UR - http://www.scopus.com/inward/record.url?scp=34547450063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547450063&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.01.052

DO - 10.1016/j.ijrobp.2007.01.052

M3 - Article

C2 - 17446002

AN - SCOPUS:34547450063

VL - 68

SP - 1326

EP - 1334

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -